NurExone Biologic Inc. is a biopharmaceutical company specializing in the development of exosome-based therapies for regenerative medicine, with a primary focus on treating central nervous system injuries such as spinal cord and traumatic brain injuries. The company’s flagship innovation, the ExoTherapy platform, enables the production of exosome-loaded nanodrugs designed for minimally invasive, targeted drug delivery—addressing significant challenges in crossing the blood-brain barrier. The lead product, ExoPTEN, targets acute spinal cord injury and is intended to promote neuron regeneration and restore motor, sensory, and functional capabilities, addressing a critical unmet need for over 250,000 new patients annually. ExoPTEN has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency, paving the way for regulatory incentives and potential exclusivity. NurExone’s business model encompasses both proprietary drug development and partnerships or licensing of its platform to other pharmaceutical companies, broadening its impact across a spectrum of neurological and tissue repair indications. The company is recognized for advancing off-the-shelf, cell-free therapies poised to transform regenerative medicine and drug delivery in the biopharmaceutical sector.